Picture of Medistim ASA logo

MEDI — Medistim ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Norway's Medistim Q2 revenue rises on own-product sales growth

Norway's Medistim Q2 revenue rises on own-product sales growth


Overview

  • Norway medical device maker's Q2 revenue grew 19.5% yr/yr to NOK 202 mln

  • Q2 operating profit (EBIT) rose 20.6% to NOK 65.3 mln, EBIT margin at 32.3%

  • Company to propose authorization for quarterly dividends at next General Meeting


Outlook

  • Company did not provide specific guidance for future quarters or full year in the press release


Result Drivers

  • OWN-PRODUCT SALES - Currency-neutral sales of Medistim's own products rose 33.6% in Q2

  • REGIONAL GROWTH - Strong currency-neutral growth in all regions, with Americas up 46.3%, APAC up 22.4%, and EMEA up 19.4%

  • DISTRIBUTOR SALES DECLINE - Third-party distributor sales in Scandinavia decreased 7% in the quarter


Company press release: ID:nObiCmSjVa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

NOK 202 mln

Q2 EBIT

NOK 65.30 mln

Q2 EBIT Margin

32.00%


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for Medistim ASA is NOK315.00, about 35.2% above its August 20 closing price of NOK233.00

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 29 three months ago


Reuters Recommended Reads

  • Aug 19 - Sweden's Redsense returns to profit in Q2 on higher sensor patch sales

  • Aug 19 - Sensirion H1 profit jumps on medical demand; lifts outlook

  • Aug 20 - Chinese medical device maker Zylox-Tonbridge's revenue rises 31%, aided by global expansion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medistim ASA

See all news